Immutep Ltd
ASX:IMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Amoy Diagnostics Co Ltd
SZSE:300685
|
CN |
|
Beijing Originwater Technology Co Ltd
SZSE:300070
|
CN |
|
L
|
Lay Hong Bhd
KLSE:LAYHONG
|
MY |
|
Montea NV
XBRU:MONT
|
BE |
|
W
|
Westrock Co
LSE:0LW9
|
US |
|
Nath Bio-Genes (I) Ltd
NSE:NATHBIOGEN
|
IN |
|
Z
|
Zhejiang Dayang Biotech Group Co Ltd
SZSE:003017
|
CN |
|
Neste Oyj
OMXH:NESTE
|
FI |
|
Jiangsu Yinhe Electronics Co Ltd
SZSE:002519
|
CN |
Immutep Ltd
Stock-Based Compensation
Immutep Ltd
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Stock-Based Compensation
AU$817.7k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Stock-Based Compensation
$16.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Stock-Based Compensation
$152m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Stock-Based Compensation
AU$1.3m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Stock-Based Compensation
AU$19.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Stock-Based Compensation
AU$940.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Stock-Based Compensation?
Stock-Based Compensation
817.7k
AUD
Based on the financial report for Dec 31, 2025, Immutep Ltd's Stock-Based Compensation amounts to 817.7k AUD.
What is Immutep Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
-22%
Over the last year, the Stock-Based Compensation growth was -22%. The average annual Stock-Based Compensation growth rates for Immutep Ltd have been -2% over the past three years , -22% over the past five years .
